News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2026-08-21 pm EDT			5-day change	1st Jan Change
33.45 ^USD	+0.12%		+4.73%	+8.60%

Aug. 21	Nordic stocks in North America, Ericsson fell 0.9 percent	FW
Aug. 20	Cancer vaccines finally garner the spotlight

All News

Mentions Relevance

Aug. 20	AlphaValue/Baader Europe Downgrades Genmab to Add, Trims PT	MT
Aug. 12	BNP Paribas Initiates Genmab at Outperform, With $40 Price Target	MT
Aug. 11	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
Aug. 07	Genmab: Q2 beat reinforces the investment story; diversification efforts remain on course
Aug. 07	Genmab A/S, H1 2026 Earnings Call, Aug 06, 2026
Aug. 07	UBS raises Genmab price target to 2,700 Danish kroner (2,600), reiterates buy	FW
Aug. 07	Genmab soars after raising its guidance
Aug. 07	Analysts upbeat on Genmab after strong Q2	FW
Aug. 07	Goldman Sachs raises Genmab target price to 2,400 Danish kroner (2,350), reiterates buy - BN	FW
Aug. 07	TD Cowen raises Genmab price target to 2,892 Danish kroner (2,851), reiterates buy	FW
Aug. 07	Jyske Bank raises Genmab target price to 2 350 Danish kroner (2 300), reiterates buy - BN	FW
Aug. 07	Nordea raises its target price for Genmab to 2,083 Danish kroner (2,015), reiterates buy	FW
Aug. 06	Genmab A/S Revises Earnings Guidance for the Year 2026	CI
Aug. 06	Genmab A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 06	Genmab Lifts FY26 Earnings Guidance	MT
Aug. 06	Genmab boosts operating profit more than expected, raises guidance (update 2)	FW
Aug. 06	Genmab A/S : Interim Report for the First Half of 2026	PU
Aug. 06	Genmab boosted operating profit more than expected, raises forecasts (update)	FW
Aug. 06	Genmab boosted operating profit more than expected	FW
Aug. 06	Genmab Announces Financial Results for the First Half of 2026	GL
Jul. 23	Stocks to Watch : Intel, Deckers, Edwards Lifesciences, Genmab	DJ
Jul. 23	Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	GL
Jul. 23	Genmab A/S and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma	CI
Jul. 22	TD Cowen Upgrades Genmab to Buy Rating, Boosts PT	MT
Jul. 22	TD Cowen Upgrades Genmab to Buy From Hold, Raises Price Target to $43 From $32	MT